BioMarin Pharmaceutical Inc. (BMRN) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $55.35 (+0.48%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 12, 2026 | Akash Tewari | Jefferies | $103.00 | +86.1% |
| Mar 3, 2026 | Eliana Merle | Barclays | $105.00 | +89.7% |
| Mar 2, 2026 | Ilya Zubkov | Loop Capital Markets | $105.00 | +89.7% |
| Feb 26, 2026 | Whitney Ijem | Canaccord Genuity | $104.00 | +87.9% |
| Feb 24, 2026 | Paul Matteis | Stifel Nicolaus | $68.00 | +22.9% |
| Dec 23, 2025 | Joon Lee | Truist Financial | $100.00 | +80.7% |
| Nov 3, 2025 | William Pickering | Tudor Pickering | $88.00 | +59.0% |
| Oct 28, 2025 | Luca Issi | RBC Capital | $66.00 | +19.2% |
| Oct 28, 2025 | Joon Lee | Truist Financial | $80.00 | +44.5% |
| Oct 28, 2025 | Sean Laaman | Morgan Stanley | $98.00 | +77.1% |
| Oct 28, 2025 | Mohit Bansal | Wells Fargo | $70.00 | +26.5% |
| Jul 15, 2025 | Akash Tewari | Wolfe Research | $95.00 | +71.6% |
| Oct 30, 2024 | Olivia Brayer | Cantor Fitzgerald | $90.00 | +62.6% |
| Oct 30, 2024 | Jack Allen | Robert W. Baird | $65.00 | +17.4% |
| Oct 30, 2024 | David Lebowitz | Citigroup | $81.00 | +46.3% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $79.00 | +42.7% |
| Oct 4, 2024 | Gena Wang | Barclays | $86.00 | +55.4% |
| Sep 18, 2024 | David Lebowitz | Citigroup | $93.00 | +68.0% |
| Sep 17, 2024 | George Farmer | Scotiabank | $78.00 | +40.9% |
| Sep 17, 2024 | Joon Lee | Truist Financial | $90.00 | +62.6% |
Top Analysts Covering BMRN
BMRN vs Sector & Market
| Metric | BMRN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.26 | 2.24 | 2.40 |
| Analyst Count | 23 | 8 | 19 |
| Target Upside | +60.3% | +11475.0% | +17.1% |
| P/E Ratio | 30.72 | 3.88 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $846M | $859M | $876M | 4 |
| 2026-09-30 | $937M | $956M | $977M | 2 |
| 2026-12-31 | $1.02B | $1.04B | $1.06B | 3 |
| 2027-03-31 | $972M | $992M | $1.01B | 3 |
| 2027-06-30 | $1.03B | $1.05B | $1.07B | 2 |
| 2027-09-30 | $1.06B | $1.08B | $1.10B | 2 |
| 2027-12-31 | $1.13B | $1.16B | $1.18B | 3 |
| 2028-12-31 | $4.18B | $4.42B | $4.66B | 9 |
| 2029-12-31 | $4.60B | $4.79B | $4.98B | 4 |
| 2030-12-31 | $4.89B | $5.09B | $5.29B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.73 | $0.93 | $1.09 | 4 |
| 2026-09-30 | $1.13 | $1.16 | $1.19 | 1 |
| 2026-12-31 | $1.34 | $1.38 | $1.42 | 2 |
| 2027-03-31 | $1.18 | $1.22 | $1.25 | 2 |
| 2027-06-30 | $1.33 | $1.36 | $1.40 | 1 |
| 2027-09-30 | $1.24 | $1.28 | $1.31 | 1 |
| 2027-12-31 | $1.47 | $1.51 | $1.55 | 2 |
| 2028-12-31 | $4.91 | $6.78 | $9.04 | 8 |
| 2029-12-31 | $7.21 | $7.60 | $7.98 | 6 |
| 2030-12-31 | $8.02 | $8.45 | $8.88 | 6 |
Frequently Asked Questions
What is the analyst consensus for BMRN?
The consensus among 23 analysts covering BioMarin Pharmaceutical Inc. (BMRN) is Buy with an average price target of $86.60.
What is the highest price target for BMRN?
The highest price target for BMRN is $135.00, set by Phil Nadeau at Cowen & Co. on 2021-12-08.
What is the lowest price target for BMRN?
The lowest price target for BMRN is $65.00, set by Jack Allen at Robert W. Baird on 2024-10-30.
How many analysts cover BMRN?
23 analysts have issued ratings for BioMarin Pharmaceutical Inc. in the past 12 months.
Is BMRN a buy or sell right now?
Based on 23 analyst ratings, BMRN has a consensus rating of Buy (2.26/5) with a +60.3% upside to the consensus target of $86.60.
What are the earnings estimates for BMRN?
Analysts estimate BMRN will report EPS of $0.93 for the period ending 2026-06-30, with revenue estimated at $859M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.